文献速递临床微生物分子诊断

非金黄色葡萄球菌mecA介导甲氧西林耐药替代试验评估

Evaluation of Surrogate Tests for the Presence of mecA-Mediated Methicillin Resistance in Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus warneri.
PubMed 文献 · J Clin Microbiol · 2020-12-17

本研究评估头孢西丁和苯唑西林微量肉汤稀释法、纸片扩散法及PBP2a免疫测定在头状葡萄球菌、溶血葡萄球菌、人型葡萄球菌和沃氏葡萄球菌中检测mecA介导耐药的效果,并与mecA PCR比较。结果显示PBP2a免疫测定与PCR 100%相关,而苯唑西林纸片扩散法假阳性率高,现行CLSI苯唑西林折点导致2.1%极重大误差和7.1%重大误差。研究促使CLSI调整了SOSA的苯唑西林MIC折点。

要点

  • PBP2a免疫测定与mecA PCR结果100%相关。
  • 苯唑西林纸片扩散法重大误差率高(20.7%–21.7%)。
  • 分子检测mecA或PBP2a评估是首选方法。

核心结论

  • PBP2a免疫测定与mecA PCR 100%相关,是替代试验中表现最佳者。
  • 没有单一表型药敏试验与mecA PCR结果在所有SOSA菌种中均高度相关。
  • 分子检测mecA或PBP2a评估是首选方法。

研究设计与样本

  • 对头状葡萄球菌、溶血葡萄球菌、人型葡萄球菌和沃氏葡萄球菌分离株进行头孢西丁和苯唑西林微量肉汤稀释法、纸片扩散法及PBP2a免疫测定。
  • 将上述表型试验结果与mecA PCR结果进行比较。

主要发现

  • PBP2a免疫测定与PCR 100%相关。
  • 现行CLSI苯唑西林折点导致2.1%极重大误差和7.1%重大误差。
  • 调整苯唑西林折点(敏感≤0.5 μg/ml;耐药≥1.0 μg/ml)后,极重大误差2.8%,重大误差0.3%。
  • 新折点下溶血葡萄球菌极重大误差6.4%,人型葡萄球菌4.0%,不可接受。
  • 苯唑西林纸片扩散法重大误差率高(20.7%–21.7%),极重大误差0–5.3%。

关键数值与推荐

  • 现行CLSI苯唑西林折点:极重大误差2.1%,重大误差7.1%。
  • 调整后苯唑西林折点(敏感≤0.5 μg/ml;耐药≥1.0 μg/ml):极重大误差2.8%,重大误差0.3%。
  • 新折点下溶血葡萄球菌极重大误差6.4%,人型葡萄球菌4.0%。
  • 苯唑西林纸片扩散法(CLSI或EUCAST折点):重大误差20.7%–21.7%,极重大误差0–5.3%。
  • 头孢西丁微量肉汤稀释法:极重大误差4.9%,重大误差1.6%。

临床怎么用

  • 实验室应知晓没有单一表型试验与mecA PCR结果在所有SOSA菌种中高度相关。
  • 首选mecA分子检测或PBP2a评估以检测SOSA的mecA介导耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Testing of staphylococci other than Staphylococcus aureus (SOSA) for mecA-mediated resistance is challenging. Isolates of Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus warneri were evaluated by cefoxitin and oxacillin broth microdilution (BMD), disk diffusion (DD), and PBP2a immunoassay, and the results were compared to mecA PCR results. No phenotypic susceptibility test correlated well with PCR results across all species, although the PBP2a immunoassay yielded 100% correlation. Oxacillin BMD testing by current Clinical and Laboratory Standards Institute (CLSI) SOSA breakpoints led to 2.1% very major errors (VMEs) and 7.1% major errors (ME). Adjusting this breakpoint up by a dilution (susceptible, ≤0.5 μg/ml; resistant, ≥1.0 μg/ml) led to 2.8% VMEs and 0.3% MEs. Among species evaluated, S. haemolyticus had unacceptable VMEs with this new breakpoint (6.4%), as did S. hominis (4.0%). MEs were acceptable by this new breakpoint, ranging from 0 to 1.2%. Oxacillin DD yielded high ME rates (20.7 to 21.7%) using CLSI or European Committee on Antimicrobial Susceptibility Testing breakpoints. VMEs ranged from 0 to 5.3%. Cefoxitin BMD led to 4.9% VMEs and 1.6% MEs. Cefoxitin DD performed best when interpreted with the CLSI SOSA breakpoint, with 1.0% VMEs and 2.9% MEs. This study led CLSI to adjust the oxacillin MIC breakpoints for SOSA. Laboratories should be aware that no individual phenotypic test correlates well across all species of SOSA with mecA PCR results. Molecular testing for mecA or evaluation for PBP2a is the preferred approach.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Humphries RM, Magnano P, Burnham CA, et al. Evaluation of Surrogate Tests for the Presence of mecA-Mediated Methicillin Resistance in Staphylococcus capitis, Staphylococcus haemolyticus, Staphylococcus hominis, and Staphylococcus warneri. J Clin Microbiol. 2020. PMID: 33115842. doi:10.1128/JCM.02290-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。